Discovery Life Sciences and Mindpeak Enhance Cancer Biomarker Testing with AI

Discovery Life Sciences and Mindpeak have formed a partnership to tackle the challenge of inconsistent biomarker interpretation in clinical trials. The collaboration aims to integrate AI-powered digital image analysis into pathology services, focusing on immunohistochemistry (IHC) and multiplex immunofluorescence (mIF). This endeavor is set to enhance biomarker quantification, reduce variability, and bolster confidence in critical drug development decisions.

Mindpeak's AI platform will pair with Discovery's biomarker services to improve interpretation consistency across pathologists. The initiative includes AI-enabled pathology workflows and advanced training for pathologists. Discovery's established Biomarker Academy further strengthens this alliance, leveraging over a decade of expertise in biomarker interpretation.

The partnership promises to enhance trial processes, ensuring more consistent and reproducible data outcomes, essential for patient stratification and therapeutic development.